Shots: • CHMP approval is based on two P-III trials i.e. DRIVE-AHEAD and DRIVE-FORWARD assessing (Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/TDF) and (Pifeltro vs darunavir +ritonavir +FTC/TDF/abacavir (ABC)/3TC)) for 48 wks.- showing its safety and efficacy • On 30 Aug- 2018 the US FDA approved Delstrigo and Pifeltro for the treatment of HIV-1 infection in adult with no prior antiretroviral treatment administering qd PO with or without food. Marketing authorization for Delstrigo and Pifeltro are under review in other countries- including Canada- Australia- and Switzerland • Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) is a combination of doravirine (100 mg)- lamivudine (3TC- 300 mg) and tenofovir disoproxil fumarate (TDF- 300 mg) administered qd FD and Pifeltro (doravirine) is a 100 mg non-nucleoside reverse transcriptase inhibitor (NNRTI) administered combining antiretroviral medicines / article | Ref: Merck | Image:  Gamelearn